Breast Cancer Clinical Trial

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Summary

This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer.

The study drugs involved in this study are:

A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO)
Hormonal (endocrine) Treatment

View Full Description

Full Description

The research study procedures include screening for eligibility and study treatment including laboratory evaluations, physical exams, questionnaires, and follow up visits.

Participants will receive HER2-directed treatment for 1 year and hormonal therapy for approximately 5 years.
It is expected that about 375 people will take part in this research study.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug combination to learn whether the drug works in treating a specific disease. "Investigational" means that the drug combination is being studied.

The drugs trastuzumab and pertuzumab are both monoclonal antibodies, which are disease-fighting proteins made by cloned immune cells. The U.S. Food and Drug Administration (FDA) has approved trastuzumab, pertuzumab, and trastuzumab + pertuzumab subcutaneous fixed dose combination (PHESGO) as treatment for HER2 positive breast cancer. The FDA has also approved hormonal therapies as treatment for hormone receptor positive breast cancer.

.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

HER2-positive T1 histologically confirmed invasive carcinoma of the breast. Patients must have node-negative (N0) or micrometastases (N1mi) breast cancer according to the AJCC 8th edition anatomic staging table.

If the patient has had a negative sentinel node biopsy, then no further axillary dissection is required, and the patient is determined to be node-negative. Axillary nodes with single cells or tumor clusters ≤ 0.2 mm by either H&E or immunohistochemistry (IHC) will be considered node-negative.
Any axillary lymph node with tumor clusters between 0.02 and 0.2cm is considered a micrometastasis. Patients with a micrometastasis are eligible. An axillary dissection is not required to be performed in patients with a micrometastasis found by sentinel node evaluation. In cases where the specific pathologic size of lymph node involvement is subject to interpretation, the overall principal investigator will make the final determination as to eligibility. The investigator must document approval in the patient medical record.
Patients who have an area of T1aN0, ER+ (defined as ≥ 10%), HER2-negative cancer in either breast, in addition to their primary HER2 positive tumor, are eligible.
For unifocal disease, all invasive disease must have been tested for ER and PR (for multifocal disease, see below). Either ER or PR must be positive, defined as ER ≥10% or PR ≥10%. ER- and PR-assays should be performed by immunohistochemical methods according to the local institution standard protocol.

HER2-positive by ASCO CAP 2018 guidelines, confirmed by central testing. See Appendix I for ASCO CAP 2018 HER2 testing guidelines.

NOTE: DCIS components will not be counted in the determination of HER2 status
NOTE: HER-2 status must be confirmed to be positive by central review prior to patient starting protocol therapy. Patients previously having had HER2 testing by NeoGenomics do not need to undergo retesting for central confirmation of HER2 status. A pathology report documenting testing by NeoGenomics should be provided at time of patient registration.
Bilateral breast cancers that individually meet eligibility criteria are allowed.
Patients with multifocal or multicentric disease are eligible as long as each tumor individually meets eligibility criteria, with the following exceptions: (1) central confirmation of HER2 status is needed only for any site of disease that is tested to be HER2-positive by local testing (unless original testing was done by NeoGenomics); (2) all areas that were locally tested for ER and PR status must be ER/PR positive (as defined above).
Patients with a history of ipsilateral DCIS are eligible as long as the patient has not received prior hormonal therapy. Patients with a history of contralateral DCIS are not eligible unless contralateral DCIS was diagnosed at least 15 years ago
≤ 95 days between the date of protocol registration and the patient's most recent breast surgery for this breast cancer

Patients must have undergone definitive breast surgery for the current malignancy. All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection

-- All margins should be clear of invasive cancer or DCIS (i.e. no tumor on ink). The local pathologist must document negative margins of resection in the pathology report. If all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed. Likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed. Radiation therapy to the conserved breast is required.

May have received up to 8 weeks of hormonal therapy as adjuvant treatment for this cancer. Patients should otherwise not have received prior hormonal therapy with the exception that hormonal therapy administered for less than 8-week duration at least 15 years ago is allowed.
Prior oophorectomy (including for cancer therapy) is allowed.
Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy.
Patients who have participated in a window study (treatment with an investigational agent prior to surgery for ≤2 weeks) are eligible. Patients must have discontinued the investigational agent at least 14 days before participation in this study.
Men and women with any menopausal status ≥18 years of age
ECOG Performance Status 0 or 1

Participants must have normal organ and marrow function as defined below:

ANC ≥ 1000/mm3
hemoglobin ≥8 g/dl
platelets ≥ 75,000/mm3
AST and ALT both <5x institutional ULN
Total bilirubin ≤ 1.5 mg/dL. For patients with Gilbert syndrome, the direct bilirubin should be Serum creatinine ≤ 2.0 mg/dL OR calculated GFR ≥ 30mL/min
Left ventricular ejection fraction (LVEF) ≥ 50%

Post-menopausal patients must meet one of the following criteria:

Prior bilateral ovariectomy/oophorectomy
Age ≥ 60 years
Age < 60 years with intact uterus and amenorrhoeic for ≥ 12 consecutive months prior to chemotherapy and/or endocrine therapy exposure (medication-induced amenorrhea is not acceptable to meet this criterion)
Age < 60 years hysterectomized and FSH and plasma estradiol levels in the postmenopausal range according to local policies prior to chemotherapy and/or endocrine therapy exposure.
Willingness to discontinue contraceptive hormonal therapy, e.g. birth control pills, prior to registration and while on study
Premenopausal patients with intact uterus must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and women less than 12 months from their last menstrual period.
Women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form of nonhormonal contraception or two effective forms of nonhormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 7 months after the last dose of antibody treatment and 3 months after the last dose of hormonal treatment.
Patients must be willing and able to sign informed consent.
Patients must be willing to provide archival tissue for research purposes.
If patient is English-speaking, must be willing to fill out patient questionnaires.

Exclusion Criteria:

Neoadjuvant or adjuvant chemotherapy for this breast cancer prior to enrollment is prohibited.

Any of the following due to teratogenic potential of the study drugs:

Pregnant women
Nursing women
Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, IUDS, surgical sterilization, abstinence, etc). Hormonal birth control methods are not permitted.
Men who are unwilling to employ adequate contraception (condoms, surgical sterilization, abstinence, etc).
Participants who are receiving any other investigational agents for treatment of breast cancer, unless specific approval is obtained from the Sponsor-Investigator.
Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge)
Patients with a history of previous invasive breast cancer.

Individuals with a history of a different malignancy are ineligible except for the following circumstances:

Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy.
individuals with the following cancer are eligible regardless of when they were diagnosed and treated: cervical cancer in situ, and non-melanoma cancer of the skin.
Intercurrent illness including, but not limited to: ongoing or active, unresolved systemic infection, renal failure requiring dialysis, active cardiac disease, prior myocardial infarction (asymptomatic changes on EKG suggestive of old MI is not an exclusion), history of CHF, current use of any therapy specifically for CHF, uncontrolled hypertension, significant psychiatric illness, or other conditions that in the opinion of the investigator limit compliance with study requirements.

Time and Motion Substudy Eligibility:

Participant must be enrolled at Dana-Farber Cancer Institute
Participant must not have discontinued pertuzumab following treatment cycle 1
Participant must be able to tolerate subcutaneous administration following cycle 1

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

375

Study ID:

NCT04569747

Recruitment Status:

Recruiting

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

Stamford Hospital
Stamford Connecticut, 06904, United States More Info
K.M. Steve Lo, MD
Contact
[email protected]
K. M. Steve Lo, MD
Principal Investigator
Winship Cancer Institute at Emory University Hospital Midtown
Atlanta Georgia, 30308, United States More Info
Ashley Trumball
Contact
[email protected]
Jane Meisel, MD
Principal Investigator
Emory University - Winship Cancer Institute
Atlanta Georgia, 30322, United States More Info
Jane Meisel, MD
Contact
[email protected]
Jane Meisel, MD
Principal Investigator
Winship Cancer Institute at Emory Saint Joseph's Hospital
Atlanta Georgia, 30342, United States More Info
Ashley Trumball
Contact
[email protected]
Jane Meisel, MD
Principal Investigator
Indiana University Health Schwarz Cancer Center
Indianapolis Indiana, 46032, United States More Info
Tarah Ballinger, MD
Contact
[email protected]
Tarah Ballinger, MD
Principal Investigator
Indiana University Health - Melvin and Bren Simon Cancer Center
Indianapolis Indiana, 46202, United States More Info
Tarah J Ballinger, MD
Contact
[email protected]
Tarah J Ballinger, MD
Principal Investigator
Indiana University Sidney and Lois Eskenazi Hospital
Indianapolis Indiana, 46202, United States More Info
Tarah Ballinger, MD
Contact
[email protected]
Tarah Ballinger, MD
Principal Investigator
Eastern Maine Medical Center (Northern Light)
Brewer Maine, 04412, United States More Info
Sarah J Sinclair, DO
Principal Investigator
Dana Farber Cancer Institite
Boston Massachusetts, 02115, United States More Info
Adrienne Waks, MD
Contact
617-632-3800
[email protected]
Adrienne Waks, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States More Info
Nadine Tung, MD
Contact
[email protected]
Nadine Tung, MD
Principal Investigator
Dana-Farber Brigham Cancer Center - Foxborough
Foxboro Massachusetts, 02035, United States More Info
Natalie Sinclair, MD
Contact
781-624-4800
[email protected]
Natalie Sinclair, MD
Principal Investigator
Dana-Farber at Milford
Milford Massachusetts, 01757, United States More Info
Natalie Sinclair, MD
Contact
[email protected]
Natalie Sinclair, MD
Principal Investigator
Dana-Farber at South Shore Hospital
Weymouth Massachusetts, 02190, United States More Info
Meredith Faggen, M.D.
Contact
781-624-4800
meredith_fa[email protected]
Meredith Faggen, MD
Principal Investigator
Dana-Farber Cancer Insitute at Londonderry Hospital
Londonderry New Hampshire, 03053, United States More Info
Stefani Freeman, RN
Contact
[email protected]
Jeanna Walsh, MD
Principal Investigator
New York University Langone Hospital - Long Island
Mineola New York, 11501, United States More Info
Sylvia Adams, MD
Contact
[email protected]
New York University Langone Health
New York New York, 10016, United States More Info
Sylvia Adams, MD
Contact
[email protected]
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States More Info
Denise A. Yardley, MD
Contact
[email protected]
Denise Yardley, MD
Principal Investigator
MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Pamela Lewis
Contact
[email protected]
Vicente Valero, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

375

Study ID:

NCT04569747

Recruitment Status:

Recruiting

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.